News
KYNB
3.795
+3.68%
0.135
Weekly Report: what happened at KYNB last week (1026-1030)?
Weekly Report · 4d ago
Weekly Report: what happened at KYNB last week (1019-1023)?
Weekly Report · 10/26 09:14
Weekly Report: what happened at KYNB last week (1012-1016)?
Weekly Report · 10/19 09:14
Kyntra Bio Price Target Announced at $35.00/Share by Maxim Group
Dow Jones · 10/13 20:35
Kyntra Bio initiated with a Buy at Maxim
TipRanks · 10/13 11:50
Weekly Report: what happened at KYNB last week (1005-1009)?
Weekly Report · 10/12 09:15
Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision
TipRanks · 10/06 20:36
Weekly Report: what happened at KYNB last week (0928-1002)?
Weekly Report · 10/05 09:15
Kyntra Bio appoints new independent director, updates governance
TipRanks · 10/01 12:00
Kyntra Bio appoints Singer to its board of directors
TipRanks · 10/01 11:05
*Kyntra Bio Appoints Andrew E. Singer to Its Bd of Directors
Dow Jones · 10/01 11:02
Press Release: Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Dow Jones · 10/01 11:00
Weekly Report: what happened at KYNB last week (0921-0925)?
Weekly Report · 09/28 09:14
Weekly Report: what happened at KYNB last week (0914-0918)?
Weekly Report · 09/21 09:14
Kyntra Bio Price Target Announced at $41.00/Share by Lake Street
Dow Jones · 09/17 13:21
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Benzinga · 09/17 13:12
Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential
TipRanks · 09/17 12:45
Kyntra Bio initiated with a Buy at Lake Street
TipRanks · 09/17 11:40
Weekly Report: what happened at KYNB last week (0907-0911)?
Weekly Report · 09/14 09:15
FibroGen Inc trading resumes
TipRanks · 09/10 17:30
More
Webull provides a variety of real-time KYNB stock news. You can receive the latest news about KYNTRA BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.